LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

LLY

1,015.09

-0.37%↓

JNJ

245.52

+0.74%↑

ABBV

224.3

-0.98%↓

NVS

163.06

-1.25%↓

MRK

121.34

+0.52%↑

Search

Bristol-Myers Squibb Co.

Open

SectorHealthcare

59.9 0.08

Overview

Share price change

24h

Current

Min

59.18

Max

60.3

Key metrics

By Trading Economics

Income

4.9B

7.1B

Sales

280M

13B

P/E

Sector Avg

17.555

110.024

Dividend yield

4.16

Profit margin

56.431

Employees

32,500

EBITDA

-2.4B

2.2B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+0.27% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.16%

2.26%

Next Earnings

30 Apr 2026

Next Dividend date

30 Apr 2026

Next Ex Dividend date

3 Apr 2026

Market Stats

By TradingEconomics

Market Cap

9.9B

124B

Previous open

59.82

Previous close

59.9

News Sentiment

By Acuity

29%

71%

78 / 351 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Bristol-Myers Squibb Co. Chart

Past performance is not a reliable indicator of future results.

Related News

5 Feb 2026, 12:14 UTC

Earnings

Bristol Myers Squibb 4Q Revenue Ticks Up on Immuno-Oncology Growth

22 Jan 2026, 12:48 UTC

Major Market Movers

Janux Shares Rise On Solid Tumor License Agreement with Bristol Myers Squibb

6 Jan 2026, 15:14 UTC

Acquisitions, Mergers, Takeovers

Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million

6 Feb 2026, 12:35 UTC

Earnings

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

5 Feb 2026, 15:25 UTC

Earnings

Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag. -- Barrons.com

5 Feb 2026, 13:10 UTC

Earnings

Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors. -- Barrons.com

5 Feb 2026, 12:17 UTC

Earnings

Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors. -- Barrons.com

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb: 2026 Guidance Excludes Impact of Any Potential Future Strategic Acquisitions, Divestitures and Impact of Future Acquired IPRD Charges and Licensing Income >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb Sees Total Worldwide Eliquis Revenue Increasing 10%-15% in 2026 Vs Yr-Ago >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb: 2026 Rev Outlook Reflects Anticipated Revenue Decline for Legacy Portfolio of About 12%-16% >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb: 2026 Legacy Portfolio Rev Decline Expected to Be Partially Offset by Continued Strength of Growth Portfolio >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb Sees 2026 Rev $46B-$47.5B >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 4Q, Which Was More Than Offset by Expected Continued Generic Impact Across Remainder of Portfolio, and Impacts From Higher U.S. Govt Channel Rebates >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb 4Q U.S. Revenue Flat at $8.56B >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb: Made Significant Progress in 2025, With Real Momentum in Growth Portfolio and Strengthened Balance Sheet That Provides Strategic Flexibility to Continue Investing in Growth Drivers >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb 4Q Growth Portfolio Revenue Rose 16% to $7.39B >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb: Have Potential to Achieve Industry-Leading, Sustainable Growth Into 2030s and Beyond >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.94B >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb 4Q Growth Portfolio Revenue Increase Primarily Driven by Immuno-Oncology Portfolio, Reblozyl, Camzyos and Breyanzi >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb 4Q Legacy Portfolio Rev Fell 15% to $5.11B >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb 4Q Adjusted Gross Margin 71.9% >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb: Latest 4Q Includes Net Impact of Loss of 60c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb Sees 2026 Adj EPS $6.05-Adj EPS $6.35 >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb 4Q Adj EPS $1.26 >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb 4Q Gross Margin 67.2% >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb 4Q Rev $12.5B >BMY

5 Feb 2026, 11:59 UTC

Earnings

Bristol Myers Squibb 4Q EPS 53c >BMY

20 Jan 2026, 21:45 UTC

Acquisitions, Mergers, Takeovers

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

20 Jan 2026, 14:53 UTC

Acquisitions, Mergers, Takeovers

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

20 Jan 2026, 12:10 UTC

Acquisitions, Mergers, Takeovers

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

Peer Comparison

Price change

Bristol-Myers Squibb Co. Forecast

Price Target

By TipRanks

0.27% upside

12 Months Forecast

Average 59.89 USD  0.27%

High 72 USD

Low 40 USD

Based on 20 Wall Street analysts offering 12 month price targets forBristol-Myers Squibb Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

20 ratings

8

Buy

11

Hold

1

Sell

Technical Score

By Trading Central

N/A / 50.57Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

78 / 351 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
help-icon Live chat